Pill Identifier App

Generic Prevacid Availability

Prevacid is a brand name of lansoprazole, approved by the FDA in the following formulation(s):

PREVACID (lansoprazole - capsule, delayed rel pellets;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: May 10, 1995
    Strength(s): 15MG [AB], 30MG [RLD] [AB]

PREVACID (lansoprazole - tablet, delayed release, orally disintegrating;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: August 30, 2002
    Strength(s): 15MG, 30MG [RLD]

Has a generic version of Prevacid been approved?

A generic version of Prevacid has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Prevacid and have been approved by the FDA:

lansoprazole capsule, delayed rel pellets;oral

  • Manufacturer: DR REDDYS LABS LTD
    Approval date: October 15, 2010
    Strength(s): 15MG [AB], 30MG [AB]

LANSOPRAZOLE (lansoprazole capsule, delayed rel pellets;oral)

  • Manufacturer: KRKA TOVARNA ZDRAVIL
    Approval date: September 16, 2013
    Strength(s): 15MG [AB], 30MG [AB]

lansoprazole capsule, delayed rel pellets;oral

  • Manufacturer: MYLAN PHARMS INC
    Approval date: November 10, 2009
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: NATCO PHARMA LTD
    Approval date: December 18, 2012
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: SANDOZ
    Approval date: April 23, 2010
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: SUN PHARMA GLOBAL
    Approval date: September 13, 2013
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: TEVA PHARMS
    Approval date: November 10, 2009
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: WOCKHARDT USA
    Approval date: September 14, 2012
    Strength(s): 15MG [AB], 30MG [AB]
  • Manufacturer: ZYDUS HLTHCARE
    Approval date: August 19, 2013
    Strength(s): 15MG [AB], 30MG [AB]

Note: No generic formulation of the following product is available.

  • lansoprazole - tablet, delayed release, orally disintegrating;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prevacid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Orally disintegrable tablets
    Patent 6,328,994
    Issued: December 11, 2001
    Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
    Assignee(s): Takeda Chemical Industries, Ltd.
    An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 .mu.m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
    Patent expiration dates:
    • May 17, 2019
    • November 17, 2019
      ✓ 
      Pediatric exclusivity
  • Rapidly Disintegrable solid preparation
    Patent 7,399,485
    Issued: July 15, 2008
    Inventor(s): Shimizu; Toshihiro & Sugaya; Masae & Nakano; Yoshinori
    Assignee(s): Takeda Pharmaceutical Company Limited
    A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.
    Patent expiration dates:
    • May 26, 2018
      ✓ 
      Drug product
    • November 26, 2018
      ✓ 
      Pediatric exclusivity
  • Orally disintegrable tablets
    Patent 7,431,942
    Issued: October 7, 2008
    Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
    Assignee(s): Takeda Pharmaceutical Company Limited
    An orally disintegrable tablet of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
    Patent expiration dates:
    • May 17, 2019
      ✓ 
      Drug product
    • November 17, 2019
      ✓ 
      Pediatric exclusivity
  • Orally disintegrable tablets
    Patent 7,875,292
    Issued: January 25, 2011
    Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
    Assignee(s): Takeda Pharmaceutical Company Limited
    An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
    Patent expiration dates:
    • May 17, 2019
      ✓ 
      Drug product
    • November 17, 2019
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web3)